Here we applied this approach to develop a bivalentvaccine against pneumococcus and S. typhi.
2
Cross-reactive seropositivity is more common in women with high anti-HPV16 antibody response and in the bivalentvaccine recipients.
3
We developed in this study a bivalentvaccine against the two viruses through a recently developed polyvalent complex platform.
4
Vaccination with the bivalentvaccine at day 1 resulted in a decreased spleen colonization by both Salmonella Infantis and Enteritidis.
5
We conducted a cost-utility analysis of screening and immunization with the bivalentvaccine for the Canadian setting from the Ministry of Health perspective.
6
In particular, the bivalentvaccine provides additional protection against HPV 31, 33, and 45 and the quadrivalent vaccine against HPV31.
7
Here, we expand our investigation of the immunogenic properties of these bivalentvaccines in mice.